DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation

Cell Death and Differentiation

Volumn 21, Issue 5, 2014, Pages 761-773

  Pellacani, D ^a   Kestoras, D ^a   Droop, A P ^a   Frame, F M ^a   Berry, P A ^a   Lawrence, M G ^b   Stower, M J ^c   Simms, M S ^d,e   Mann, V M ^d,e   Collins, A T ^a   Risbridger, G P ^b   Maitland, N J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b MONASH UNIVERSITY   (Australia)

^c YORK HOSPITAL   (United Kingdom)

^d CASTLE HILL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF HULL   (United Kingdom)

Author keywords

cancer stem cells; CpG island; DNA methylation; prostate cancer

Indexed keywords

GLUTATHIONE TRANSFERASE P1;

ANIMAL EXPERIMENT; ARTICLE; CCND2 GENE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CPG ISLAND; CSTA GENE; DKK3 GENE; DNA METHYLATION; DOWN REGULATION; GENE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LDHB GENE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE EPITHELIUM; S100A14 GENE; SFN GENE; THBS1 GENE; ANIMAL; BAGG ALBINO MOUSE; CELL GROWTH; EPITHELIUM CELL; GENETICS; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; TUMOR CELL CULTURE; XENOGRAFT;

ANIMALS; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; DNA METHYLATION; DOWN-REGULATION; EPITHELIAL CELLS; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, INBRED BALB C; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84898050049     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.202     Document Type: Article

References (60)

1. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7: 21-33. (Pubitemid 41828945)
2. Sell S. On the stem cell origin of cancer. Am J Pathol 2010; 176: 2584-2494.
3. Miller SJ, Lavker RM, Sun T-T. Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications. Biochim Biophys Acta 2005; 1756: 25-52. (Pubitemid 41317558)
4. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011; 17: 313-319.
5. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951. (Pubitemid 41713363)
6. El-Alfy M, Pelletier G, Hermo LS, Labrie F. Unique features of the basal cells of human prostate epithelium. Microsc Res Tech 2000; 51: 436-446.
7. Humphrey PA. Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J Clin Pathol 2007; 60: 35-42. (Pubitemid 46142669)
8. Nagle RB, Ahmann FR, McDaniel KM, Paquin ML, Clark VA, Celniker A. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res 1987; 47: 281-286. (Pubitemid 17002136)
9. Polson ES, Lewis JL, Celik H, Mann VM, Stower MJ, Simms MS et al. Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells. Nat Commun 2013; 4: 1623.
10. Shen MM, Wang X, Economides KD, Walker D, Abate-Shen C. Progenitor cells for the prostate epithelium: roles in development, regeneration, and cancer. Cold Spring Harb Symp Quant Biol 2008; 73: 529-538.
11. Wang ZA, Shen MM. Revisiting the concept of cancer stem cells in prostate cancer. Oncogene 2011; 30: 1261-1271.
12. Oldridge EE, Pellacani D, Collins AT, Maitland NJ. Prostate cancer stem cells: are they androgen-responsive? Mol Cell Endocrinol 2012; 360: 14-24.
13. Goldstein AS, Stoyanova T, Witte ON. Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells. Mol Oncol 2010; 4: 385-396.
14. Rane JK, Pellacani D, Maitland NJ. Advanced prostate cancer-a case for adjuvant differentiation therapy. Nat Rev Urol 2012; 9: 595-602.
15. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010; 28: 1057-1068.
16. Cedar H, Bergman Y. Programming of DNA methylation patterns. Annu Rev Biochem 2012; 81: 97-117.
17. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012; 13: 484-492.
18. Clark SJ, Melki J. DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene 2002; 21: 5380-5387. (Pubitemid 34983474)
19. Goering W, Kloth M, Schulz WA. DNA methylation changes in prostate cancer. Methods Mol Biol 2012; 863: 47-66.
20. Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med 2013; 5: 169ra10.
21. Meiers I, Shanks JH, Bostwick DG. Glutathione S-transferase pi (GSTP1) hypermethyla-tion in prostate cancer: review 2007. Pathology 39: 299-304.
22. Nelson CP, Kidd LC, Sauvageot J, Isaacs WB, De Marzo AM, Groopman JD et al. Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4, 5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res 2001; 61: 103-109. (Pubitemid 32095707)
23. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissec-tion. Am J Pathol 2003; 163: 923-933. (Pubitemid 37040128)
24. Nelson WG, De Marzo AM, Deweese TL, Lin X, Brooks JD, Putzi MJ et al. Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann N Y Acad Sci 2001; 952: 135-144. (Pubitemid 34060016)
25. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64: 1975-1986. (Pubitemid 38339443)
26. van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA. Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol 2001; 195: 563-570. (Pubitemid 34030794)
27. Lang SH, Smith J, Hyde C, Macintosh C, Stower M, Maitland NJ. Differentiation of prostate epithelial cell cultures by matrigel/stromal cell glandular reconstruction. In Vitro Cell Dev Biol Anim 2006; 42: 273-280. (Pubitemid 44851885)
28. Attard G, Rizzo S, Ledaki I, Clark JP, Reid AHM, Thompson A et al. A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies. Prostate 2009; 69: 1507-1520.
29. Birnie R, Bryce SD, Roome C, Dussupt V, Droop A, Lang SH et al. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol 2008; 9: R83.
30. Frame FM, Hager S, Pellacani D, Stower MJ, Walker HF, Burns JE et al. Development and limitations of lentivirus vectors as tools for tracking differentiation in prostate epithelial cells. Exp Cell Res 2010; 316: 3161-3171.
31. Maitland NJ, Frame FM, Polson ES, Lewis JL, Collins AT. Prostate cancer stem cells: do they have a basal or luminal phenotype? Horm Cancer 2011; 2: 47-61.
32. Ananthanarayanan V, Deaton RJ, Yang XJ, Pins MR, Gann PH. Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer. BMC Cancer 2006; 6: 73.
33. Robertson KD, Keyomarsi K, Gonzales FA, Velicescu M, Jones PA. Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells. Nucleic Acids Res 2000; 28: 2108-2113. (Pubitemid 30255532)
34. Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 1995; 31: 14-24.
35. Liu P, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, Dalton WB et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 2006; 66: 4011-4019.
36. Oudes AJ, Campbell DS, Sorensen CM, Walashek LS, True LD, Liu AY. Transcriptomes of human prostate cells. BMC Genomics 2006; 7: 92.
37. Easwaran H, Johnstone SE, Van Neste L, Ohm J, Mosbruger T, Wang Q et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res 2012; 22: 837-849.
38. Raney BJ, Cline MS, Rosenbloom KR, Dreszer TR, Learned K, Barber GP et al. ENCODE whole-genome data in the UCSC genome browser (2011 update). Nucleic Acids Res 2011; 39: D871-D875.
39. Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, Peehl DM et al. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 2011; 21: 1017-1027.
40. Pearson JF, Hughes S, Chambers KF, Lang SH. Polarized fluid movement and not cell death, creates luminal spaces in adult prostate epithelium. Cell Death Differ 2009; 16: 475-482.
41. Taylor RA, Toivanen R, Frydenberg M, Pedersen J, Harewood L et al. Australian Prostate Cancer Bioresource. Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status. Stem Cells 2012; 30: 1087-1096.
42. Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD et al. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 2001; 61: 8135-8142. (Pubitemid 33091604)
43. Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 2001; 159: 1815-1826. (Pubitemid 33062524)
44. Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 2004; 91: 540-552.
45. Song JZ, Stirzaker C, Harrison J, Melki JR, Clark SJ. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 2002; 21: 1048-1061. (Pubitemid 34174517)
46. Hudson DL, Guy AT, Fry P, O'Hare MJ, Watt FM, Masters JR. Epithelial cell differentiation pathways in the human prostate: identification of intermediate phenotypes by keratin expression. J Histochem Cytochem 2001; 49: 271-278. (Pubitemid 32113389)
47. Sproul D, Kitchen RR, Nestor CE, Dixon JM, Sims AH, Harrison DJ et al. Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns. Genome Biol 2012; 13: R84.
48. Schulz WA, Hatina J. Epigenetics of prostate cancer: beyond DNA methylation. J Cell Mol Med 2006; 10: 100-125. (Pubitemid 44874294)
49. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117: 3539-3545. (Pubitemid 39206394)
50. Pellacani D, Packer RJ, Frame FM, Oldridge EE, Berry PA, Labarthe M-C et al. Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer. Mol Cancer 2011; 10: 94.
51. Hager S, Frame FM, Collins AT, Burns JE, Maitland NJ. An internal polyadenylation signal substantially increases expression levels of lentivirus-delivered transgenes but has the potential to reduce viral titer in a promoter-dependent manner. Hum Gene Ther 2008; 19: 840-850.
52. Chambers KF, Pearson JF, Aziz N, O'Toole P, Garrod D, Lang SH. Stroma regulates increased epithelial lateral cell adhesion in 3D culture: a role for actin/cadherin dynamics. PLoS One 2011; 6: e18796.
53. Chambers KF, Pearson JF, Pellacani D, Aziz N, Guzvic M, Klein CA et al. Stromal upregulation of lateral epithelial adhesions: Gene expression analysis of signalling pathways in prostate epithelium. J Biomed Sci 2011; 18: 45.
54. Ha°vik AB, Brandal P, Honne H, Dahlback H-SS, Scheie D, Hektoen M et al. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Transl Med 2012; 10: 36.
55. Dahl JA, Collas P. A rapid micro chromatin immunoprecipitation assay (microChIP). Nat Protoc 2008; 3: 1032-1045. (Pubitemid 351818692)
56. Rivera-Gonzalez GC, Droop AP, Rippon HJ, Tiemann K, Pellacani D, Georgopoulos LJ et al. Retinoic acid and androgen receptors combine to achieve tissue specific control of human prostatic transglutaminase expression: a novel regulatory network with broader significance. Nucleic Acids Res 2012; 40: 4825-4840.
57. Li L-C, Okino ST, Dahiya R. DNA methylation in prostate cancer. Biochim Biophys Acta 2004; 1704: 87-102. (Pubitemid 39195351)
58. Jerónimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JWF, Clark SJ et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 2011; 60: 753-766.
59. Ongenaert M, Van Neste L, De Meyer T, Menschaert G, Bekaert S, Van Criekinge W. PubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic Acids Res 2008; 36: D842-D846. (Pubitemid 351149833)
60. Lauss M, Visne I, Weinhaeusel A, Vierlinger K, Noehammer C, Kriegner A. MethCancerDB-aberrant DNA methylation in human cancer. Br J Cancer 2008; 98: 816-817. (Pubitemid 351272608)